Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
Discover innovative and validated solutions for developing obesity therapeutics. These solutions enable effective screening, characterisation, and potency testing for commercial lot release of novel drugs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.
Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3
By Dr Raminderal Singh (Hitchhikers AI and 20/15 Visioneers, Nina…
How GPCR agonists, including antibodies, are shaping the future of metabolic care
By Dr Cedric Ververken
New research improves the safety and effectiveness of ADC cancer treatments
By Drug Target Review
How AI will reshape pharma in 2025
By Carrie Haslam
Beyond the lab: neuroscience
Download this free report to explore the future of neuroscience and current developments in drug discovery. It features interviews with experts discussing challenges and historical influences in the field, the role of neuroscientists in addressing environmental issues, and personal journeys in neuroscience.
In vivo CAR T: Faster, cheaper, and more effective cancer…
By David Fontana (Chief Operating Officer at Umoja Biopharma)
Oncology advances through the lens of women in STEM
By Dr. Pooja Hingorani (Senior Medical Director of Oncology Early…